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Abstract C-CAM, a ubiquitously expressed cell adhesion
molecule belonging to the carcinoembryonic antigen family,
appears as two co-expressed isoforms, C-CAM-L and C-CAM-
S, with different cytoplasmic domains, that can form homo-
dimers in epithelial cells. In addition, C-CAM-L has been found
in large molecular weight forms suggesting posttranslational,
covalent modification. Here we have investigated the possibility
that the cytoplasmic domain of C-CAM-L can act as a
transglutaminase substrate. Glutathione S-transferase fusion
proteins of the cytoplasmic domains of rat and mouse C-CAM-
L as well as free cytoplasmic domains, released by thrombin
cleavage from the fusion proteins, were converted into covalent
dimers by tissue transglutaminase. These results demonstrate
that the cytoplasmic domains of rat and mouse C-CAM-L are
substrates for tissue transglutaminase, and lend support to the
notion that higher molecular weight forms of C-CAM-L are
formed by transglutaminase modification.
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1. Introduction
Rat C-CAM (rC-CAM), together with the homologous hu-
man and mouse biliary glycoproteins (hC-CAM and mC-
CAM) belong to the carcinoembryonic antigen (CEA) sub-
group of the immunoglobulin (Ig) superfamily [1]. Alternative
splicing of these highly glycosylated, transmembrane proteins
generates a number of isoforms which contain either 71^73
amino acid (C-CAM-L) or 10^12 amino acid long (C-CAM-S)
cytoplasmic domains [1]. Both the long and short cytoplasmic
domain isoforms have been shown to mediate intercellular
adhesion [2]. The long cytoplasmic domain isoforms can be
phosphorylated on tyrosine residues [3^5] and have been dem-
onstrated to bind tyrosine kinases of the src family [3] and the
tyrosine phosphatases SHP-1 and SHP-2 [1,5] supporting the
notion that these proteins are important transducers or regu-
lators of cellular signals. Both rC-CAM-L and mC-CAM-L,
also known as Bgp1, have been shown to act as suppressors of
tumour growth [6,7].
We have recently demonstrated that C-CAM is organised
as non-covalently linked dimers within the membranes of epi-
thelial cells [8]. In addition, the detection of C-CAM-L-con-
taining species with apparent molecular masses twice that of
monomeric C-CAM, in extracts of rat liver plasma mem-
branes [8,9], led us to propose [8] that a population of C-
CAM-L dimers may become covalently modi¢ed, perhaps
by the action of tissue transglutaminase.
Transglutaminases (EC 2.3.2.13) are a group of enzymes
which catalyse a Ca2-dependent acyl transfer reaction in
which amide bonds are formed between Q-carboxamide groups
of peptide-bound glutamine residues and primary amines [10].
This commonly results in the formation of proteolytically re-
sistant, Q-glutamyl-O-lysine isopeptide bonds within or between
proteins. Transglutaminases have been implicated in diverse
cellular processes, including covalent cross-linking of ¢brin
clots [11], formation of the corni¢ed envelope of keratinocytes
[12], stabilisation of extracellular matrices [13^15], formation
of a detergent-insoluble protein sca¡old in cells undergoing
apoptosis [16], and regulation of cellular growth [17].
Although little is known about the endogenous substrates of
tissue transglutaminase, which is found in all cells studied, it
has been demonstrated that this enzyme can be activated by a
physiological increase of the intracellular calcium concentra-
tion. Treatment of A431 cells with epidermal growth factor
led to calcium-triggered transglutaminase cross-linking of the
intracellular protein lipocortin I [18], and in hepatocytes tissue
transglutaminase caused downregulation of the receptor for
hepatocyte growth factor [17]. Both primary structure and
conformation appear to determine whether proteins can act
as transglutaminase substrates, with reactive glutamines often
located on solvent-exposed or £exible areas of the protein
[10,19]. Thus, while there is no consensus sequence for trans-
glutaminase-catalysed modi¢cation, the two glutamine resi-
dues present in the cytoplasmic domain of rC-CAM-L have
features often found in known transglutaminase substrates
[15,19] in that they are located immediately adjacent to one
another and close to a number of charged and polar amino
acids.
Using recombinant proteins consisting of the cytoplasmic
domain of C-CAM-L fused to glutathione S-transferase
(GST), we now demonstrate that C-CAM-L is a substrate
for tissue transglutaminase and that this reaction results in
the formation of covalently linked homo-dimers of C-CAM-L.
2. Materials and methods
2.1. Reagents
Guinea pig liver transglutaminase, monodansylcadaverine (MDC),
cystamine and thrombin were purchased from Sigma. A rabbit poly-
clonal anti-peptide antibody (L2), raised against a sequence present in
the cytoplasmic domain of rC-CAM-L, has been described previously
[8] and reacts with both rC-CAM-L and mC-CAM-L. A polyclonal
antibody against GST was from Pharmacia and molecular mass
standards for SDS-PAGE were from Bio-Rad.
2.2. Preparation of recombinant proteins
The construction of recombinant GST-mC-CAM-L (GST-Bgp1)
using the pGEX-2T vector has been described previously [5]. GST-
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rC-CAM-L was made by inserting the cytoplasmic domain of rC-
CAM-L from the pRAX vector [2] into a pGEX-2T vector (Pharma-
cia). For this purpose the forward primer 5P-AGAGGATC-
CAATGGCTACTTCCTTTATTCCAGG-3P and the backward pri-
mer 5P-AGCTGCGAATTCAATGTCACTTCTTTTT-3P were used
for ampli¢cation of the cytoplasmic region of rC-CAM-L by PCR
using the pRAX vector as template. The PCR product was cut with
BamHI and EcoRI and ligated into the corresponding sites within the
pGEX-2T vector. This insert encodes amino acids 445^519 of the rC-
CAM-L. Proteins were produced in Escherichia coli BL21. Protein
synthesis was induced by IPTG (0.2 mM). Puri¢cation of the GST
fusion proteins was performed by a⁄nity adsorption on glutathione-
Sepharose according to a standard protocol from the manufacturer
(Pharmacia).
2.3. Thrombin cleavage of fusion proteins
Fusion proteins in Tris-bu¡ered saline (TBS), pH 7.4, were cleaved
by incubation with thrombin (10 units/mg protein) for 4 h at room
temperature, followed by dilution with TBS, pH 7.4, to the appropri-
ate concentration for transglutaminase treatment.
2.4. Transglutaminase treatment of recombinant proteins
Samples (20 Wl) of GST alone, GST-rC-CAM-L or GST-mC-CAM-
L (1 mg/ml) in TBS, pH 7.4, containing either 5 mM CaCl2 or 5 mM
EDTA and varying amounts (5^20 mU) of guinea pig liver transglu-
taminase were incubated at 37‡C for 30 min. In some experiments, the
transglutaminase inhibitors MDC (0.5 mM) or cystamine (1 mM)
were included in the reaction mixtures. Reactions were stopped by
the addition of an equal volume of 2USDS sample bu¡er [20] con-
taining 10 mM DTT and samples were incubated at 100‡C for 5 min
prior to SDS-PAGE.
2.5. SDS-PAGE and immunoblotting
SDS-PAGE was performed according to Laemmli [20] and proteins
were detected by staining with Coomassie brilliant blue or immuno-
chemically, as described previously [8]. Immunoreactive proteins were
visualised using an enhanced chemiluminescence (ECL) detection sys-
tem (Amersham).
3. Results and discussion
To investigate the possibility that C-CAM-L could act as a
substrate for tissue transglutaminase we prepared recombi-
nant proteins consisting of the cytoplasmic domains of rat
and mouse C-CAM-L fused to GST. After puri¢cation,
GST appeared on Coomassie blue-stained gels as a 29 kDa
band (Fig. 1, lane 1), while both GST-rC-CAM-L (Fig. 1, lane
2) and GST-mC-CAM-L (Fig. 1, lane 3) migrated as single
bands, whose apparent Mrs of about 36 kDa were consistent
with their expected values.
It has been reported that GST appears as a dimer under
native conditions [21], and after chemical cross-linking with
3,3P-dithiobis(sulphosuccinimidyl) propionate (DTSSP) we
also observed that the majority of the GST molecules mi-
grated at the position of dimers in SDS-PAGE (data not
shown). However, GST migrated as a monomer both prior
to (Fig. 2, lane 1) and after (Fig. 2, lane 2) treatment with
transglutaminase. In contrast, addition of transglutaminase to
GST-rC-CAM-L (Fig. 2, lane 3) resulted in the appearance of
an additional band (Fig. 2, lane 4), whose apparent Mr of 70
kDa indicated that it was a dimeric form of the fusion protein.
rC-CAM-L has only two glutamine residues in its cytoplasmic
domain [1]. They are immediately adjacent to each other at
positions 496 and 497, and could serve as acyl donors in the
transglutaminase reaction. The conservation of these two glu-
tamine residues in both human and mouse C-CAM-L [1] sug-
gested that these proteins would also act as transglutaminase
substrates. Indeed, addition of transglutaminase to a recombi-
nant protein consisting of GST fused to the long cytoplasmic
domain of mC-CAM-L (Fig. 2, lane 5) also resulted in the
appearance of a 70 kDa band (Fig. 2, lane 6). These results
suggest that the cytoplasmic domain of C-CAM-L acts as a
substrate for tissue transglutaminase and indicate that the
observed cross-linking is not the result of stabilisation of
GST dimers.
Transglutaminases are Ca2-dependent enzymes [10], and
cross-linking of both GST-rC-CAM-L (not shown) and
GST-mC-CAM-L (Fig. 2, lane 7) was critically dependent
upon the presence of Ca2 and abrogated by the inclusion
of EDTA in the reaction bu¡er (Fig. 2, lane 8). Cross-linking
of the fusion proteins was also blocked by both MDC (Fig. 2,
lane 9) and cystamine (Fig. 2, lane 10), two structurally un-
related transglutaminase inhibitors.
While transglutaminases show considerable speci¢city to-
wards acyl donor glutamine residues in substrate proteins,
they appear to be much less selective towards amine donor
lysines [19]. Our results did not therefore allow us to predict if
cross-linking occurred between cytoplasmic domains alone or
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Fig. 1. SDS-PAGE analysis of recombinant proteins. Puri¢ed GST
(lane 1), GST-rC-CAM-L (lane 2) and GST-mC-CAM-L (lane 3)
were electrophoresed on 8% polyacrylamide gels and stained with
Coomassie brilliant blue. The migration positions of Mr markers
are indicated.
Fig. 2. Transglutaminase treatment of recombinant proteins. GST
(lanes 1 and 2), GST-rC-CAM-L (lanes 3 and 4) and GST-mC-
CAM-L (lanes 5 and 6), in TBS, pH 7.4, containing 5 mM CaCl2
were incubated without (lanes 1, 3 and 5) or with (lanes 2, 4 and 6)
10 mU transglutaminase for 30 min at 37‡C, subjected to SDS-
PAGE and immunoblotted with anti-GST antibody (lanes 1 and 2)
or antibody L2 (lanes 2^6). GST-mC-CAM-L in TBS, pH 7.4, con-
taining either 5 mM CaCl2 (lanes 7, 9 and 10) or 5 mM EDTA
(lane 8) was incubated with transglutaminase alone (lanes 7 and 8)
or together with the transglutaminase inhibitors MDC (lane 9) or
cystamine (lane 10) and analysed with antibody L2. The migration
positions of Mr markers are indicated.
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involved the participation of the GST fusion partner. How-
ever, failure to alter the extent of transglutaminase-dependent
cross-linking by addition of increasing amounts of free GST
(not shown) suggested that amide bond formation likely oc-
curred between cytoplasmic domain polypeptides.
The recombinant fusion proteins used in this study contain
a thrombin cleavage site, allowing the release of the constitu-
ent GST and cytoplasmic domain moieties, which enabled us
to assess directly the ability of the cytoplasmic domain to act
as a transglutaminase substrate. Thrombin cleavage of GST-
rC-CAM-L gave rise to a single cytoplasmic domain polypep-
tide with an apparent Mr of 7^8 kDa, recognised by antibody
L2 (Fig. 3, lane 1). Upon addition of transglutaminase in the
presence of Ca2, an additional band of about 16 kDa was
detected (Fig. 3, lane 2) consistent with formation of dimers of
the cytoplasmic domain. Transglutaminase treatment of
thrombin-cleaved GST-mC-CAM-L (Fig. 3, compare lanes 3
and 4) gave identical results. Taken together, our data clearly
demonstrate that the cytoplasmic domain of C-CAM-L acts
as a substrate for tissue transglutaminase. Since the major
products of this reaction are covalently cross-linked dimers
of the cytoplasmic domain, these results further support our
suggestion that mutual interactions between cytoplasmic do-
main sequences contribute to homo-dimerisation of C-CAM-
L within plasma membranes [8]. However, the ability of the
short cytoplasmic domain isoform, C-CAM-S, to form homo-
dimers [8] suggests that the ectodomain is also involved in this
reaction. This notion is supported by our unpublished obser-
vations that a soluble form of the ectodomain of rC-CAM can
dimerise.
Tissue transglutaminase, which can be activated by e.g.
growth factor-induced increase of the intracellular calcium
concentration [18], is abundantly expressed in liver [10] and
it is of particular interest that it is in this tissue that we [8] and
others [9] have identi¢ed a number of high molecular weight
C-CAM-L-containing species. The abundance of a group of
proteins with an apparent Mr twice that of monomeric C-
CAM, coupled with our demonstration that C-CAM is dis-
tributed as non-covalently linked dimers within plasma mem-
branes, led us to propose that a population of C-CAM-L
dimers [8] may become covalently modi¢ed. The demonstra-
tion, in the present study, that C-CAM-L acts as a substrate
for transglutaminase and that the major products of this re-
action are C-CAM-L dimers lends support to this notion.
Tissue transglutaminase has been implicated in the process
of apoptosis and large protein species, formed by transgluta-
minase-catalysed cross-linking, have been identi¢ed in rat liver
[16,22]. However, unlike the C-CAM-L homo-dimers identi-
¢ed here, these aggregates have apparent molecular masses
greater than 5U103 kDa, contain multiple protein constitu-
ents, and appear to represent the highly cross-linked envelopes
of cells undergoing programmed cell death [22].
Dimer formation is not a prerequisite for cell adhesion,
suggesting that dimers may instead be involved in C-CAM-
mediated signalling [8]. The ¢nding that human C-CAM-L
can bind protein tyrosine kinases of the src family [3] and
that mouse C-CAM-L binds the protein tyrosine phospha-
tases SHP-1 and SHP-2 [1,5] led us to propose a model in
which adhesion and signalling are regulated by the C-CAM
monomer/dimer ratio within cells [1,23]. In the monomeric
state, C-CAM-L may more readily bind tyrosine kinases, lead-
ing to the generation of a positive growth signal. SHP-1 and
SHP-2, which have two phosphotyrosine-binding SH2 do-
mains, are suggested to bind to C-CAM-L homo-dimers,
which might lead to termination of the positive growth signal.
C-CAM-L dimers, covalently cross-linked by transglutami-
nase, would, according to this model, be predicted to be
locked into a form which suppresses cellular growth. It is
interesting to note therefore, that when transfected into highly
tumorigenic cells, both rC-CAM-L [7] and mC-CAM-L [6],
but not their short cytoplasmic domain counterparts, act as
suppressors of tumour growth. An intriguing and testable
hypothesis, suggested by our current studies, is that these
long cytoplasmic domain isoforms may be covalently modi¢ed
by tissue transglutaminase, leading to increased stabilisation
of C-CAM-L dimers and a potentiation of a negative growth
signal. Such a role for tissue transglutaminase is in agreement
with observations in other laboratories that increased trans-
glutaminase activity modi¢es cancer cells [24] and has negative
e¡ects on cellular growth [17].
The precise role of C-CAM dimer formation and transglu-
taminase stabilisation of C-CAM-L homo-dimers remains to
be elucidated. However, the conservation of the two immedi-
ately adjacent glutamine residues in rat, mouse and human C-
CAM-L and our demonstration that both rat and mouse C-
CAM-L can act as transglutaminase substrates strongly sug-
gests that transglutaminase-catalysed modi¢cation is likely to
be a physiologically important modulator of C-CAM func-
tion.
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